Idogen: €2.9m

Case

Idogen’s technology platform allows cells from the patient’s blood to be reprogrammed outside the body to dendritic cells with the capacity to specifically counteract adverse immune reactions. Idogen was granted € 2.9M from the SME Instrument HORIZON 2020, phase 2.

“We warmly recommend GAEU Consulting services to Life Science companies seeking professional advice within Horizon 2020 funding.”

- VD Lars Hedbys